CONFLICTS OF INTEREST
Pilar Ossorio is on the ethics advisory board for Astellas Pharma U.S., Inc. She has received less than $3000 in consulting fees from Astellas each year for the past two years. To the best of her knowledge, Astellas has no active immunotherapy products on the market or in development. Astellas does have a regenerative medicine, cell therapy product in development in the US (described on the firm's website). Krishanu Saha is a member of the forum on Regenerative Medicine (NASEM) and the Center for Cell Manufacturing (CMaT, NSF). These organizations provided reimbursement for travel expenses for meetings related to immunotherapy manufacturing.